Fortune
In Fortune, BCG’s François Candelon and Matthieu Gombeaud, along with BCG alumna Georgie Stokol, discuss how startups are enabling the synthetic biology revolution by creating new competitively priced processes and products that are more sustainable. According to an analysis by the BCG Henderson Institute, synthetic biology could disrupt industries that account for as much as 30% of global GDP by 2030, as companies come to grips with this emergent technology. The authors encourage CEOs in every industry to take five steps to capitalize on the financial and environmental benefits generated by synthetic biology technologies.